Interatrial block, P terminal force or fragmented QRS do not predict new-onset atrial fibrillation in patients with severe chronic kidney disease

Hellman, Tapio; Hakamäki, Markus; Lankinen, Roosa; Koivuviita, Niina; Pärkkä, Jussi; Kallio, Petri; Kiviniemi, Tuomas; Airaksinen, K. E. Juhani; Järvisalo, Mikko J.; Metsärinne, Kaj

doi:10.1186/s12872-020-01719-3

Table 1 Electrocardiogram characteristics of patients according to incidence of new-onset AF during follow-up

From: Interatrial block, P terminal force or fragmented QRS do not predict new-onset atrial fibrillation in patients with severe chronic kidney disease

	No AF (N = 136)	Incident AF (N = 29)	p
ECG
PR-interval^a
mean (median) ms	176 (168)	180 (168)	0.48
P-wave duration^a
mean (median) ms	117 (120)	118 (120)	0.79
Biphasic P-waves (> 1)^b	5 (3.7)	2 (6.9)	0.61
Terminal P negativity depth
mean (median) mV^c	0.5 (0.5)	0.6 (0.5)	0.39
Terminal P negativity duration
mean (median) mm^c	56 (50)	53 (60)	0.65
IAB^d	75 (55.1)	17 (58.6)	0.84
*PTF > 0.04 mms**^e	33 (24.3)	11 (37.9)	0.17
LAE^f	113 (83.1)	24 (82.8)	1.0
QRS duration mean (median) ms	98 (95)	97 (96)	0.94
QTc duration mean (median) ms	442 (439)	426 (449)	0.44
QRS axis mean (median) degrees	25 (25)	15 (15)	0.15
fQRS^g	121 (89.0)	23 (79.3)	0.22
fQRS positive leads mean (median)	5 (5)	4 (4)	0.07
fQRS positive in anterior leads alone^h	5 (3.7)	2 (6.9)	0.61
fQRS positive in lateral leads aloneⁱ	9 (6.6)	0 (0)	0.36
fQRS positive in inferior leads alone^j	31 (22.8)	8 (27.6)	0.63
fQRS positive in ant + lat leads	3 (2.2)	0 (0)	1.0
fQRS positive in ant + inf leads	20 (14.7)	5 (17.2)	0.78
fQRS positive in lat + inf leads	33 (24.3)	8 (27.6)	0.81
fQRS positive in ant + lat + inf leads	20 (14.7)	0 (0)	0.03
Echocardiography
LA diameter mean (median) mm^*	40 (39)	44 (42)	0.01
EF mean (median) %	65 (65)	65 (66)	0.22
Laboratory tests
NT-ProBNP median (IQR) ng/l	808 (1632)	1390 (5064)	0.10
Clinical charateristics
CHA₂DS₂-VASc-score median (IQR)	2 (2)	3 (3)	0.03

^*data is missing in 28 (17.0%) cases
^ameasured in lead II; ^b measured in leads II, III and aVF; ^c measured in lead V₁; ^d defined according to ECG-criteria (total P-wave duration ≥120 ms in lead II ± more than one biphasic P-waves in leads II, III or aVF); ^e defined according to ECG-criteria (the product of the duration (in seconds) and depth (in millimeters) of the terminal negative portion of P-wave in lead V₁); ^f defined according to ECG-criteria (total P-wave duration ≥120 ms in lead II ± more than one biphasic P-waves in leads II, III or aVF; or duration of terminal negative portion of P-wave in lead V₁ > 40 ms or depth of terminal negative portion of P-wave in lead V₁ > 1 mm); ^g defined according to ECG-criteria (presence of a notched R or S wave or the presence of one or more additional R waves (R’) or, in the presence of a wide QRS complex (> 120 ms), more than two notches in R or S waves in two contiguous leads corresponding to a major coronary artery, respectively.); ^h measured in leads V₁-V₄; ⁱ measured in leads V₅-V₆ and I and aVL; ^j measured in leads II-III and aVF
Values in parentheses are % unless stated otherwise. ECG = electrocardiogram; IAB = interatrial block; PTF = P terminal force; LAE = left atrial enlargement; fQRS = fragmented QRS; LA = left atrium; EF = ejection fraction; NT-ProBNP = N-terminal pro b-type natriuretic peptide; IQR = inter-quartile range; CHA₂DS₂-VASc = congestive heart failure, hypertension, age ≥ 75 years (doubled), diabetes mellitus, prior stroke, transient ischemic attack or thromboembolism (doubled), vascular disease, age 65 to 74 years and sex category (female, unless < 65 years and no other risk factors)

Back to article page

ISSN: 1471-2261

Contact us

Submission enquiries: bmccardiovasculardisorders@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cardiovascular Disorders

Contact us